Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.

Viruses - 30 Jun 2023

Devan Pooja, Tiong Kai Le Ashley, Neo Jean Ee, Mohan Babu P, Wijarnpreecha Karn, Tam Yew Chong Steve, Coppola Nicola, Preda Carmen Monica, Wong Yu Jun

Abstract excerpt

About 5% of chronic hepatitis C (CHC) patients experienced treatment failure with direct-acting antiviral (DAA) treatment. The global data on the practice and treatment outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in DAA-experienced CHC patients remains sparse. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of SOF/VEL/VOX as a salvage treatment in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Liver Neoplasms

Share to Ribavirin

Share to Sofosbuvir

Share to Sustained Virologic Response

Source

Open in PubMed Open full text

Identifiers

PMID: 37515176
DOI: 10.3390/v15071489
PMCID: PMC10384139

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.PMID 37515176Read ↗

Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan.Semantic proximity Read ↗

Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.Semantic proximity Read ↗

Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir retreatment in hepatitis C patients with different genotypes with DAAs failure in East ChinaSemantic proximity Read ↗

Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).Semantic proximity Read ↗

Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.Semantic proximity Read ↗

Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.Semantic proximity Read ↗

Real-World Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment Naive and Experienced Chronic Hepatitis C Patients: A Single-Center ExperienceSemantic proximity Read ↗

A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.Semantic proximity Read ↗

Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.Semantic proximity Read ↗

Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.Semantic proximity Read ↗

Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.Semantic proximity Read ↗

Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.